Q2 2025

Filed Aug 7, 2025 · 10-Q · 38 days after period end · 0001339970-25-000009

Q2 2025 · 10-Q

Revenue

$0.00

— vs Q2 2024

Net Income

-$19.53M

N/M vs Q2 2024

EPS Diluted

-$0.22

N/M vs Q2 2024

Operating Income-$20,313,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$0.00	$0.00	$0.00	—
Net Income	-$19.53M	-$16.31M	-$12.34M	-$12.42M
EPS Diluted	-$0.22	-$0.23	-$0.22	-$0.44

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR